Laurent Mathiot
Overview
Explore the profile of Laurent Mathiot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frenel J, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39773562
Background: The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the...
2.
Richard M, Moreau R, Croyal M, Mathiot L, Frenel J, Campone M, et al.
J Extracell Biol
. 2024 Dec;
3(12):e70013.
PMID: 39691590
Extracellular vesicles (EVs) are cell-derived small membrane structures that transport various molecules. They have emerged as potential circulating biomarkers for monitoring responses to cancer therapies. This study aimed to comprehensively...
3.
Mathiot L, Raimbourg J
Clin Lung Cancer
. 2024 Nov;
26(1):e20-e21.
PMID: 39567320
No abstract available.
4.
Mathiot L, Baldini C, Letissier O, Hollebecque A, Bahleda R, Gazzah A, et al.
Curr Oncol Rep
. 2024 Jul;
26(10):1236-1248.
PMID: 39066847
Purpose Of Review: Antibody-drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges...
5.
Aubert M, Mathiot L, Vegas H, Ouldamer L, Linassier C, Augereau P, et al.
Oncologist
. 2024 May;
29(7):e910-e917.
PMID: 38768082
Background: In women, ovarian cancer is the eighth most frequent cancer in incidence and mortality. It is often diagnosed at advanced stages; relapses are frequent, with a poor prognosis. When...
6.
Mathiot L, Combarel D, Cagnat J, Delahousse J, Ouali K, Marabelle A, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38702147
Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an...
7.
Mathiot L, Nigen B, Goronflot T, Hiret S, Doucet L, Pons-Tostivint E, et al.
Clin Lung Cancer
. 2024 Jan;
25(3):244-253.e2.
PMID: 38218680
Background: The prognostic impact of TP53 mutations in advanced or metastatic nonsquamous non-small-cell lung cancer (nsNSCLC) patients treated with chemotherapy and/or immune checkpoint inhibitors (ICI) remains unclear. Materials And Methods:...
8.
Nigen B, Goronflot T, Herbreteau G, Mathiot L, Sagan C, Raimbourg J, et al.
Lung Cancer
. 2023 Aug;
184:107321.
PMID: 37586178
Background: Although brain metastases (BM) at diagnosis are common in non-squamous NSCLC patients (ns-NSCLC), they have been mostly excluded from randomized trials. The aim of this retrospective study was to...
9.
Mathiot L, Herbreteau G, Robin S, Fenat C, Bennouna J, Blanquart C, et al.
Curr Oncol
. 2022 May;
29(5):3748-3758.
PMID: 35621690
Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). mutations involved around 0.2-0.8% of NSCLC patients,...